This post has been archived and contains information that may be out of date.
CHA has issued a members-only summary, prepared by Health Policy Alternatives, Inc., of the supplemental federal fiscal year (FFY) 2022 inpatient prospective payment system (IPPS) final rule.
This post has been archived and contains information that may be out of date.
CHA has issued a members-only summary, prepared by Health Policy Alternatives, Inc., of the proposed notice of benefit and payment parameters for 2023 issued by the Centers for Medicare & Medicaid Services (CMS). Comments are due to CMS by 2 p.m. (PT) on Jan. 27.
This post has been archived and contains information that may be out of date.
The Centers for Medicare & Medicaid Services (CMS) has issued its proposed rule for the 2023 Medicare Advantage (MA) and Part D plan year.
This post has been archived and contains information that may be out of date.
Based on requests from stakeholders, including CHA, the Department of Health Care Services has released guidance on the reimbursement requirements associated with the California Advancing and Innovating Medi-Cal (CalAIM) major organ transplant changes.
This post has been archived and contains information that may be out of date.
The Centers for Medicare & Medicaid Services (CMS) has released additional resources that can help facilities and providers prepare for the independent dispute resolution (IDR) process included in the No Surprises Act (NSA), which took effect on Jan. 1.
This post has been archived and contains information that may be out of date.
The Centers for Medicare & Medicaid Services (CMS) released a new Healthcare Common Procedure Coding System (HCPCS) code for VEKLURY™ (remdesivir) antiviral medication when administered in an outpatient setting.
This post has been archived and contains information that may be out of date.
Over the past several weeks, the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) has made several changes and updates to the distribution and allocation of currently available treatments for COVID-19, including monoclonal antibodies and oral antivirals.
This post has been archived and contains information that may be out of date.
On Jan. 8, Gov. Newsom signed Executive Order N-2-22, outlawing price-gouging for at-home COVID-19 test kits until March 31, 2022. Specifically, sellers of these tests may not charge a price that is more than 10% greater than the price they charged on Dec. 1, 2021, unless:
This post has been archived and contains information that may be out of date.
On Jan. 6, the U.S. Department of Health and Human Services (HHS) updated its COVID-19 hospital reporting requirements (see the HHS FAQs) in response to changes in the pandemic.
This post has been archived and contains information that may be out of date.
On Jan. 5, the Centers for Disease Control and Prevention (CDC) endorsed the recommendation made earlier that day by its Advisory Committee on Immunization Practices that eligibility for a single booster dose of the Pfizer-BioNTech vaccine be expanded to ages 12-15.